{
    "clinical_study": {
        "@rank": "73854", 
        "arm_group": [
            {
                "arm_group_label": "FTD", 
                "arm_group_type": "Experimental", 
                "description": "Subjects with frontotemporal disorder (FTD)."
            }, 
            {
                "arm_group_label": "CN", 
                "arm_group_type": "Experimental", 
                "description": "Cognitively normal (CN) subjects."
            }, 
            {
                "arm_group_label": "AD", 
                "arm_group_type": "Experimental", 
                "description": "Subjects with Alzheimer's disease (AD)."
            }
        ], 
        "brief_summary": {
            "textblock": "Study 18F-AV-45-010 is designed to evaluate the cerebral uptake of florbetapir 18F as\n      measured by PET imaging in frontotemporal disorder (FTD) in comparison to cognitively normal\n      volunteers and subjects with Alzheimer's disease (AD)."
        }, 
        "brief_title": "Imaging Characteristics of Florbetapir 18F in Patients With Frontotemporal Dementia, Alzheimer's Disease and Normal Controls.", 
        "completion_date": {
            "#text": "April 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Alzheimer's Disease", 
            "Frontotemporal Dementia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Alzheimer Disease", 
                "Dementia", 
                "Frontotemporal Dementia", 
                "Aphasia, Primary Progressive", 
                "Pick Disease of the Brain"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        AD:\n\n          -  Male or female >= 50 years of age\n\n          -  Meet National Institute of Neurological and Communicative Disorders and Stroke\n             (NINCDS) criteria for probable AD and have a Mini Mental State Examination (MMSE)\n             score at screening between 10 and 24 inclusive\n\n          -  Have a caregiver who can report on their mental status and activities of daily living\n             (ADL)\n\n          -  Give informed consent or have a caregiver give consent with subject assent.\n\n        FTD:\n\n          -  Male or female >= 45 years of age\n\n          -  Meet consensus criteria for FTD and have mild to moderate disease severity. Have a\n             caregiver who can report on their mental status and ADL\n\n          -  Give informed consent or have a caregiver give consent with subject assent.\n\n        CN:\n\n          -  Male or female >= 45 years of age\n\n          -  Have and MMSE >= 29\n\n          -  Give informed consent\n\n        Exclusion Criteria:\n\n          -  Have a history or a current clinically significant neurologic disease (other than AD\n             or FTD, as applicable), a diagnosis of other dementing/neurodegenerative disease, or\n             a diagnosis of mixed dementia\n\n          -  Evidence from MRI or other biomarkers that suggests an etiology of dementia other\n             than AD or FTD, as applicable or in the case of CN subjects evidence indicating the\n             presence of AD, FTD or other types of neurologic pathology\n\n          -  Have current clinically significant cardiovascular disease, screening ECG\n             abnormalities, psychiatric disease, endocrine or metabolic disease, pulmonary, renal\n             or hepatic impairment, cancer or infectious disease\n\n          -  Have a recent history of alcohol or substance abuse or dependence\n\n          -  Women of childbearing potential who are not permanently surgically sterile, or are\n             not refraining from sexual activity while not using adequate contraception.\n\n          -  Require medications with a narrow therapeutic window, are receiving any\n             investigational medications, or have participated in a trial with investigational\n             medications within the last 30 days\n\n          -  Have ever participated in a study with an amyloid targeting agent\n\n          -  Have had a radiopharmaceutical imaging or treatment procedure within 7 days of the\n             imaging, other than as defined in the protocol"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "45 Years"
        }, 
        "enrollment": {
            "#text": "28", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "June 27, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01890343", 
            "org_study_id": "18F-AV-45-010"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "FTD", 
                    "CN", 
                    "AD"
                ], 
                "description": "Subjects received a one-time intravenous (IV) bolus injection of 300 megabecquerels (MBq) florbetapir 18F.", 
                "intervention_name": "florbetapir 18F", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Florbetapir F 18", 
                    "18F-AV-45", 
                    "Amyvid"
                ]
            }, 
            {
                "arm_group_label": "FTD", 
                "description": "FTD subjects received a one-time IV bolus injection of 185 MBq of 18F-FDG.", 
                "intervention_name": "18F-FDG", 
                "intervention_type": "Drug", 
                "other_name": [
                    "FDG", 
                    "fluorodeoxyglucose (18F)", 
                    "fludeoxyglucose (18F)"
                ]
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "June 27, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Manchester", 
                    "country": "United Kingdom", 
                    "zip": "M20 3LJ"
                }, 
                "name": "Research Site"
            }
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Study Evaluating the Imaging Characteristics of Florbetapir 18F (18F-AV-45) in Patients With Frontotemporal Dementia Compared to Patients With Alzheimer's Disease and Normal Controls.", 
        "overall_official": {
            "affiliation": "Avid Radiopharmaceuticals", 
            "last_name": "Chief Medical Officer", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "United Kingdom: Research Ethics Committee"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "Two readers blinded to all clinical information classified florbetapir Positron Emission Tomography (PET) images as either positive for amyloid or negative for amyloid.", 
                "measure": "Qualitative Amyloid Image Assessment", 
                "safety_issue": "No", 
                "time_frame": "50-60 min after injection"
            }, 
            {
                "description": "Standardized Uptake Value ratios (SUVRs) were calculated for the following regions of interest (ROI): mesial temporal lobe, temporal lobe, frontal lobe, anterior cingulate cortex, posterior cingulate cortex, parietal lobe, occipital lobe, central subcortical and the brainstem. SUVR is the ratio of tracer uptake in a predefined ROI, relative to uptake in the cerebellar grey matter.", 
                "measure": "Quantitative Amyloid Image Assessment", 
                "safety_issue": "No", 
                "time_frame": "50-60 minutes after injection"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01890343"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Avid Radiopharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Avid Radiopharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2009", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}